Pfizer Inc. (PFE) Stock Rating Lowered by Jefferies Group
Pfizer Inc. (NYSE:PFE) was downgraded by equities researchers at Jefferies Group to a “hold” rating in a report released on Thursday.
PFE has been the subject of a number of other reports. Piper Jaffray Cos. set a $54.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, August 23rd. Bank of America Corp. set a $40.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, August 22nd. Credit Suisse Group AG restated an “outperform” rating and issued a $40.00 price target on shares of Pfizer in a research note on Monday, August 22nd. Argus restated a “buy” rating and issued a $39.00 price target on shares of Pfizer in a research note on Tuesday, October 4th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $40.00 price target on shares of Pfizer in a research note on Tuesday, August 23rd. Eleven investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $38.78.
Pfizer (NYSE:PFE) opened at 33.07 on Thursday. The company’s 50 day moving average price is $34.14 and its 200-day moving average price is $34.26. The stock has a market cap of $200.59 billion, a price-to-earnings ratio of 29.32 and a beta of 0.86. Pfizer has a 12-month low of $28.25 and a 12-month high of $37.39.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/13/pfizer-inc-pfe-stock-rating-lowered-by-jefferies-group.html
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. During the same period in the prior year, the company earned $0.56 EPS. The firm’s revenue was up 10.9% on a year-over-year basis. On average, analysts forecast that Pfizer will post $2.46 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be issued a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.63%. Pfizer’s dividend payout ratio is currently 95.24%.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. P. R. Herzig & Company acquired a new position in Pfizer during the fourth quarter worth $1,101,000. Jennison Associates increased its position in Pfizer by 108.2% in the third quarter. Jennison Associates now owns 9,550,121 shares of the biopharmaceutical company’s stock worth $299,969,000 after buying an additional 4,963,367 shares in the last quarter. Terra Nova Asset Management increased its position in Pfizer by 2.0% in the third quarter. Terra Nova Asset Management now owns 17,587 shares of the biopharmaceutical company’s stock worth $552,000 after buying an additional 340 shares in the last quarter. Verde Servico Internacionais acquired a new position in Pfizer during the fourth quarter worth $24,213,000. Finally, Atalanta Sosnoff Capital increased its position in Pfizer by 12.1% in the fourth quarter. Atalanta Sosnoff Capital now owns 1,935,494 shares of the biopharmaceutical company’s stock worth $62,478,000 after buying an additional 209,124 shares in the last quarter. Institutional investors and hedge funds own 69.66% of the company’s stock.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.